BJMO - , issue ,
S. Aspeslagh MD, PhD, V. Kruse MD, PhD, E. De Langhe , P. Jacques , O. Malaise , D. Elewaut , B. Lauwerys , R. Wittoek , Y. Piette , Prof B. Neyns MD, PhD
Immunotherapy has become a standard of care for patients with many different advanced solid tumors. However, boosting the immune system can induce immune related side effects, referred to as “immune-related adverse events” (irAEs). Because oncologists are not always familiar with these inflammatory autoimmune syndromes, the BSMO immunotaskforce has launched the immunomanager website which summarizes the treatment options for the most frequent irAEs including endocrine (e.g. hypo- and hyperthyroidism), digestive (e.g. colitis), pneumological (e.g. pneumonitis), dermatological and other types of irAEs. In the near future, the BSMO immunotaskforce plans to review these recommendations with Belgian organ specialists and their associations. We believe that through collaborations between organ specialists and oncologists we will be able to establish better recommendations, resulting in a better outcome for cancer patients who develop an irAE during immunotherapy.
Read moreBJMO - volume 12, issue 9, february 2018
S. Aspeslagh MD, PhD, V. Kruse MD, PhD, E. De Langhe , P. Jacques , O. Malaise , D. Elewaut , B. Lauwerys , R. Wittoek , Y. Piette , Prof B. Neyns MD, PhD
Immunotherapy has become a standard of care for patients with many different advanced solid tumors. However, boosting the immune system can induce immune related side effects, referred to as “immune-related adverse events” (irAEs). Because oncologists are not always familiar with these inflammatory autoimmune syndromes, the BSMO immunotaskforce has launched the immunomanager website which summarizes the treatment options for the most frequent irAEs including endocrine (e.g. hypo- and hyperthyroidism), digestive (e.g. colitis), pneumological (e.g. pneumonitis), dermatological and other types of irAEs. In the near future, the BSMO immunotaskforce plans to review these recommendations with Belgian organ specialists and their associations. We believe that through collaborations between organ specialists and oncologists we will be able to establish better recommendations, resulting in a better outcome for cancer patients who develop an irAE during immunotherapy.
Read moreBJMO - 12, issue 3, february 2018
S. Aspeslagh MD, PhD
BJMO - 12, issue 3, february 2018
X. Wang , G. El Hachem MD, W. Bekolo , L. Dal Lago , A. Georgala MD, T. Pepersack , S. Aspeslagh MD, PhD, L. Buisseret MD, T. Gil MD, A. Awada MD, PhD
Top
